Celldex Therapeutics (CLDX) stock

Antibody medicines , market cap $2.2B

Antibody medicines

Worth $2.2B

$30.65

-1.89%

As of Tuesday's close · Live for Pro members at the open

Quality Score

-3

Poor

In its industry

#178of 281

Biotech

Checks firing

2of 14

Choppy

From 52-week high

-32.1%

under its best in a year

CLDX's Quality Score fell 2 points on Tue, Nov 10, to -3. Buying slipped from its highest in 20 days (3 chart checks stopped).

Follow CLDX's trial news. Pro members can get an alert when Celldex Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CLDX files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextLate 2026“Topline data from this study are expected to be presented in late 2026.”Trial data · SEC filing · Nov 5

Cash$650M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30 · the company says “through 2028”

Why CLDX rose 8% since Nov 5

Up 8% from Nov 5 to Nov 10.

Celldex Therapeutics rose 8% from Nov 5 to Nov 10. 6 points of it came on Nov 6, the session after its Nov 5 results.

Sources: Price history, Nov 10, 2026; SEC filing, Nov 5, 2026

1 more reason, free with an account →The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on CLDX

Key facts on CLDX
Holding it back	Sales down 94% on the year
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind CLDX's -3, free with an account →5 more reasons behind CLDX's -3, for Pro members.

What's next

Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

Cash$650M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30 · the company says “through 2028”

CLDX catalysts

Coming up

After its last 4 reports it closed +1.9% on average, higher 3 of 4 times.

What's next for CLDX, and how long its cash lasts

Next step the company has named

Late 2026“Topline data from this study are expected to be presented in late 2026.”Trial data · SEC filing · Nov 5

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway: Efficacy, Safety and Tolerability of Barzolvolimab Versus Placebo in Adults With Cold Induced Urticaria and Symptomatic Dermographism Inadequately Controlled by H1-antihistamines (EMBARQ - ColdU and SD)Phase 3 · Recruiting · 240 people · main data estimated Jun 2028 · NCT07266402

6 more trials, 1 more milestone and 20 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 10 quarters

$650M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “through 2028” (8-K, Nov 5).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Nov 5, 2026)
At-the-market share sales program (S-3ASR, filed Nov 5, 2026)

For Pro members: 3 raises and their amounts, and the share count against a year ago.

Insiders

SVP & General Counsel Freddy A. Jimenez sold 4,166 shares on Dec 4, 2025.

From Form 4: open-market buys and sales only.

Get an alert when Anthony Marucci buys or sells

For Pro members: every trade, and Anthony Marucci’s 9 filings and quotes.

Get an alert when CLDX files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why CLDX scores -3

Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means

+2Chart checks 2 of 14 firing right now, one point each
−1Long-term trend below a falling 200-⁠day average

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth subtractsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
News adds

No effect today: Run-up, Size, and Persistence.

What every line is worth, and the reason behind it, on CLDX and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:13 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when CLDX's Quality Score turns up

A free account. No card.

How CLDX ranks in Biotech

CLDX is #178 of 281 by Quality Score.

How CLDX ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	CGEMCullinan Therapeutics		Open for its score
	CGONCG Oncology		Open for its score
	CLYMClimb Bio		Open for its score
	COAGHemab Therapeutics		Open for its score
178	CLDXCelldex Therapeutics	2/14	-3

When does CLDX report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 107 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CLDX reported on Nov 5, 2026

The quarter

A loss of $0.96 a share, from $1.01.

“The decrease in revenue was primarily due to a decrease in services performed under our manufacturing and research and development agreements with Rockefeller University.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

CLDX's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The increase in R&D expenses was primarily due to an increase in barzolvolimab clinical trial and contract manufacturing expense as well as an increase in employee headcount to support the development of barzolvolimab.”

From its results filing (SEC filing · Nov 5)

2 more sentences, for Pro members.

The numbers

Market value: $2.2B; today
Sales: $158K; down 93.9% on the year
Free cash flow: -$260M; last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CLDX: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+1.9%+0.4%+5.7%

May 7Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026After close	After close	-1.5%	+5.7%	not yet
Aug 6, 2026After close	After close	+0.8%	+0.4%	+2.5%
May 7, 2026After close	After close	+4.9%	+1.9%	-2.6%

CLDX closed higher after 3 of its last 4 reports.

All 4 reports, and CLDX's Quality Score going into each

CLDX sales and profit by year

Sales and profit by year

Sales grew in three of the last seven years, to $1.5M in 2025. It lost money in each of the three years.

CLDX has 2 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on CLDX, and all 14 on every stock.Get in free →

CLDX RSI today: 50.7, below its 50-day and 200-day averages

Not scored

RSI 50.7, MACD above signal, below both averages. Not scored.13 readings

The deep dive on CLDX

What it does and how it makes money3 findingsAn operating loss of $287M in fiscal 2025, on $1.54M of sales.Annual report, filed Feb 25, 2026
Where it stands2 findingsFor Pro members2 findings on where CLDX stands: its cash, debt, and share count, for Pro members
What changed in its filings1 findingRockefeller University made up 93% of its revenue in fiscal 2025, down from 100% in fiscal 2024.SEC filing · Feb 25, 2026
Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades CLDX, for Pro members

6 more findings on CLDX, each with its source, for Pro members.

CLDX share count over time

18% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of CLDX outstanding, as filed
Shares outstanding	As of
78.5M	Oct 28, 2026
78.5M	Jul 29, 2026
78.5M	Apr 29, 2026
66.6M	Feb 13, 2026

Offerings, shelves, and splits of CLDX, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Nov 5, 2026
Raised $300M in a sale of shares, about 14% of its market value	Apr 2, 2026
Raised $400.4M in a sale of shares, about 18% of its market value	Mar 1, 2024
Set up an at-the-market program for up to $300M of shares, about 14% of its market value	Feb 26, 2024

CLDX's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Samuel Bates MartinSVP and CFO · no trades on file
Freddy A. JimenezSVP & General Counsel · 1 trade
Ronald PepinSr. VP & CBO · no trades on file

See insider trades by person

Which ETFs hold CLDX?

In ETFs: CLDX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Celldex Therapeutics

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

198 employeesHampton, NJcelldex.com

What Celldex Therapeutics says it competes with

“The biotechnology and pharmaceutical industry is intensely competitive and subject to rapid and significant technological change.”

From its annual report, SEC filing · Feb 25, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on CLDX and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn CLDX's score around: 9 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

See CLDX's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: CLDX's Quality Score is -3 (Poor), #178 of 281 in Biotech.

What does CLDX's Quality Score say?

CLDX scores -3 today, which Breakaway calls Poor. It is #178 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Up 8% from Nov 5 to Nov 10. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CLDX's Quality Score?

CLDX scores -3 today, which Breakaway calls Poor (below zero). That is #178 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CLDX's -3.

When does CLDX report earnings?

Expected to report Thu Feb 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. CLDX closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.